IO 102

Drug Profile

IO 102

Alternative Names: IDOlong; IO102

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Herlev Hospital; IO Biotech
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 13 Apr 2018 Efficacy data from a phase I trial in Malignant melanoma released by IO Biotech before April 2018 (IO Biotech pipeline, April 2018)
  • 12 Mar 2018 IO Biotech signs a clinical collaboration agreement with Merck and Co for conduction of the phase I/II KEYNOTE-764 trial in Non-small cell lung cancer
  • 12 Mar 2018 IO Biotech and Merck & Co plan the phase I/II KEYNOTE-764 trial for Non-small cell lung cancer (Combination therapy, Metastatic disease, First-line therapy) (NCT03562871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top